Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of essential thrombocythemia on in-hospital outcomes and thrombotic complications in patients hospitalized with COVID-19: A national inpatient sample analysis (2016–2022)

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAbdulmoiz Aljafari

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds increased thrombotic complications and prolonged hospital stay in COVID-19 patients with essential thrombocythemia, highlighting unique risks.

Key Points

  • Thrombotic complications were significantly higher in COVID-19 patients with essential thrombocythemia, with increased rates of pulmonary embolism and ischemic stroke.
  • The mortality rate was lower in ET patients at 9.6% compared to 11.3% in non-ET, indicating a 12.9% relative reduction in mortality risk.
  • Patients with ET also experienced an average increase of 2.91 days in length of stay during hospitalization for COVID-19.
  • Findings call for optimized risk stratification and management strategies for patients with essential thrombocythemia during COVID-19.

Cite This Study

Abdulmoiz Aljafari (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df82https://doi.org/10.1182/blood-2025-5604
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data2025
  2. 2Impact of COVID-19 infection on hospitalization outcomes in patients with myeloproliferative neoplasms: Analysis of the national inpatient sample 2020–20212025
  3. 3Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.2025
  4. 4P149 | Acute and long-term management of venous thromboembolism through the post-COVID-19 pandemic era2025
  5. 5Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada2025